BML-210

Catalog Number P013-5MG

Catalog Number P013-25MG



FEATURES

- Potent HDAC inhibitor
- Increases A549 acetylated histone levels
- Inhibits transcription factor FOXO3 by SIRT1

INTRODUCTION

Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation. BML-210 is a small molecule inhibitor of HDAC with an IC_{50} value of 5-10 µM when tested in HeLa cell nuclear extracts. BML-210 also inhibits the deacetylation of the transcription factor FOXO3 by mammalian SIRT1 in cells oxidatively stressed by hydrogen peroxide.

FORM:	Tan powder
MOLECULAR WEIGHT:	339.4
STORAGE:	4°C, desiccated
FORMULA:	$C_{20}H_{25}N_3O_2$
CAS NUMBER:	537034-17-6
OTHER NAMES:	N-phenyl-N'-(2-Aminophenyl)hexamethylenediamide, N1-(2-aminophenyl)-N8-phenyloctanediamine
USES:	Soluble to 25 mg/mL in DMSO or 10 mg/mL in warm Ethanol

REFERENCES:

Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol., 2:10, 551-8. (2006).

Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol. 549:(1-3), 9-18 (2006).

info@ArborAssays.com • www.ArborAssays.com